%0 Journal Article
%T Vitamin D: Pharmacokinetics and Safety When Used in Conjunction with the Pharmaceutical Drugs Used in Cancer Patients: A Systematic Review
%A Deborah A. Kennedy
%A Kieran Cooley
%A Becky Skidmore
%A Heidi Fritz
%A Tara Campbell
%A Dugald Seely
%J Cancers
%D 2013
%I MDPI AG
%R 10.3390/cancers5010255
%X Vitamin D has reported anti-cancer and anti-inflammatory properties modulated through gene transcription and non-genomic signaling cascades. The purpose of this review was to summarize the available research on interactions and pharmacokinetics between vitamin D and the pharmaceutical drugs used in patients with cancer. Hypercalcemia was the most frequently reported side effect that occurred in high dose calcitriol. The half-life of 25(OH)D 3 and/or 1,25(OH) 2D 3 was found to be impacted by cimetidine; rosuvastatin; prednisone and possibly some chemotherapy drugs. No unusual adverse effects in cancer patients; beyond what is expected from high dose 1,25(OH) 2D 3 supplementation, were revealed through this review. While sufficient evidence is lacking, supplementation with 1,25(OH) 2D 3 during chemotherapy appears to have a low risk of interaction. Further interactions with vitamin D 3 have not been studied.
%K vitamin D
%K calcitriol
%K pharmacokinetics
%K drug interactions
%K systematic review
%U http://www.mdpi.com/2072-6694/5/1/255